Intuitive Surgical (NASDAQ:ISRG) Director Gary Guthart Sells 10,000 Shares of Company Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Gary Guthart sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $457.34, for a total transaction of $4,573,400.00. Following the completion of the sale, the director directly owned 1,194,530 shares in the company, valued at approximately $546,306,350.20. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Intuitive Surgical Trading Down 2.8%

Shares of ISRG stock opened at $468.52 on Friday. The firm’s 50 day moving average is $408.22 and its 200 day moving average is $432.27. The stock has a market capitalization of $162.41 billion, a P/E ratio of 56.65, a PEG ratio of 3.32 and a beta of 1.45. Intuitive Surgical, Inc. has a 12 month low of $328.57 and a 12 month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The business had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same period in the previous year, the business earned $2.40 EPS. Intuitive Surgical’s revenue was up 21.7% compared to the same quarter last year. On average, equities analysts predict that Intuitive Surgical, Inc. will post 9.37 EPS for the current year.

Hedge Funds Weigh In On Intuitive Surgical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ISRG. Fairscale Capital LLC grew its holdings in Intuitive Surgical by 3.5% during the 3rd quarter. Fairscale Capital LLC now owns 645 shares of the medical equipment provider’s stock worth $279,000 after acquiring an additional 22 shares during the last quarter. Beaumont Financial Advisors LLC raised its stake in shares of Intuitive Surgical by 3.8% in the third quarter. Beaumont Financial Advisors LLC now owns 627 shares of the medical equipment provider’s stock worth $255,000 after acquiring an additional 23 shares during the last quarter. Hughes Financial Services LLC lifted its position in shares of Intuitive Surgical by 40.7% during the third quarter. Hughes Financial Services LLC now owns 83 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 24 shares in the last quarter. W.G. Shaheen & Associates DBA Whitney & Co lifted its position in shares of Intuitive Surgical by 1.0% during the first quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 2,542 shares of the medical equipment provider’s stock worth $1,172,000 after purchasing an additional 25 shares in the last quarter. Finally, Blue Fin Capital Inc. grew its stake in shares of Intuitive Surgical by 0.5% during the first quarter. Blue Fin Capital Inc. now owns 4,794 shares of the medical equipment provider’s stock valued at $2,210,000 after purchasing an additional 25 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Da Vinci system placements rose 28% year over year to 546 in Q3 2026, while net placements increased 40%, pointing to continued demand for Intuitive Surgical’s robotic-surgery systems and expansion of its installed base. Article: ISRG System Placements Rise 28%
• Neutral Sentiment: The placements increase may reflect multisystem orders and upgrades, rather than a broad-based upswing in hospital capital-equipment budgets. That leaves open whether the strong pace can be sustained. Article: ISRG System Placements Rise 28%: Is Capital Equipment Demand Rising?
• Negative Sentiment: Two directors disclosed share sales: Gary Guthart sold 10,000 shares (0.83% of his position), and Craig Barratt sold 1,150 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which may temper—but not eliminate—their significance as a sentiment overhang. SEC filing: Gary Guthart transaction SEC filing: Craig Barratt transaction

Wall Street Analyst Weigh In

ISRG has been the topic of a number of analyst reports. Wall Street Zen upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Royal Bank Of Canada cut their target price on Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating for the company in a research note on Wednesday, October 21st. Leerink Partners set a $503.00 target price on Intuitive Surgical and gave the company an “outperform” rating in a report on Wednesday, October 21st. Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Wednesday, October 21st. Finally, Robert W. Baird increased their price target on shares of Intuitive Surgical from $513.00 to $550.00 and gave the stock an “outperform” rating in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $493.54.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.